Long-term outcome of pomalidomide therapy in myelofibrosis

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 66-68

  Begna, Kebede H ^a   Pardanani, Animesh ^a   Mesa, Ruben ^a   Litzow, Mark R ^a   Hogan, William J ^a   Hanson, Curtis A ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; LENALIDOMIDE; POMALIDOMIDE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL; CLINICAL TRIAL; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATION; MYELOFIBROSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY NEUROPATHY; SPLENOMEGALY; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84155169034     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22233     Document Type: Article

References (18)

1. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322.
2. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106: 1974-1984.
3. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164.
4. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
5. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288-296.
6. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.
7. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial. J Clin Oncol 2004; 22: 424-431.
8. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 116: 4436-4438.
9. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760-4766.
10. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21: 1827-1828.
11. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
12. Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011; 118: 899-902.
13. Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol 2011; 86: 96-98.
14. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129-130.
15. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011; 25: 301-304.
16. Pardanani A, Begna K, Finke C, et al. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343-345.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymhoid Tissues. Lyon, France: IARC press; 2008.
18. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.